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ABSTRACT
Introduction: In France, over recent years, the
prescription rate of antipsychotic (AP) remained stable
in children and adolescents. Prescription of second-
generation antipsychotics increased, whereas
prescription of first-generation antipsychotics
decreased. Off-label prescriptions are very frequent in
this population. Adverse events (AEs) in youth treated
with AP are common and may be severe. AEs have
hitherto been poorly monitored in naturalistic studies
independent from industry.
Method and analysis: We describe a French
prospective multicentre study in an AP-naïve paediatric
population named Etude de la Tolérance des
AntiPsychotique chez l’Enfant (ETAPE). The study
started in April 2013. So far, 200 patients have been
included. The inclusion criteria are: male or female
inpatients aged from 6 to 18 years, treated with an AP
drug for less than 28 days, never been treated or having
received AP for less than 3 months, discontinued at
least 6 months prior to inclusion. These assessments of
AE are performed at inclusion, as well as at 3, 6, 9 and
12 months after the introduction of the AP. The
monitoring period will end in May 2016.
Ethics and dissemination: The study protocol was
approved by the Ethics Committee ‘Sud Méditerrané V’
(number 12.082) and by the French National Agency for
Medicines and Health Products Safety (number 2012-
004546-15). All patients and their parents signed
informed consent on enrolment in the study. We will
submit the results of the study to relevant journals and
offer national and international presentations. This study
will enable better characterisation of the prescription of
AP drugs. The results will further help to develop quality
standards and recommendations for monitoring AE
during the prescription of AP.
Trial registration number: NCT02007928.
BACKGROUND
The prescription of psychotropic drugs has in-
creased in the paediatric population all over
the world since about 15 years. This increase
varies widely, depending on the country and
compounds, ranging from 1.5 to 5 times in
many European countries and the USA.1–4 In
the paediatric population, this increase is linked
to a major expansion of the prescription of
second-generation antipsychotics (SGAs). That
is explained, in large part, by the lower occur-
rence of adverse events (AEs) than with ﬁrst-
generation antipsychotic (FGA) treatment.5–8 In
France, whereas SGA prescriptions are increas-
ing and FGA prescriptions are decreasing over
the period 2006–2013, antipsychotic (AP) dis-
pensing rates are stable in persons aged 0–25
years.1 In the USA, AP use increased from 2006
to 2010 for adolescents and young adults but
not for children aged 12 years or younger.2
SGAs have been proven to be effective for
treating several conditions in children and
adolescents.9 As of March 2010, aripiprazole,
olanzapine, quetiapine and risperidone are
Food and Drug Administration (FDA)-approved
medications for bipolar mania in children
and adolescents (age 10–17 years; except
olanzapine, age 13–17 years) and for adoles-
cent schizophrenia (age 13–17 years). In add-
ition, aripiprazole and risperidone are also
FDA-approved medications for behavioural dis-
turbances (irritability and aggression) associated
with autism and/or intellectual disabilities in
children and adolescents (age 6–17 years).10
However, naturalistic studies underline that
SGAs are prescribed for many off-label in-
dications in paediatric patients in several
countries.11–13 In France, only two SGAs
have been granted market authorisation: (1)
risperidone for severe behavioural disorders
in mental retardation and for autistic syn-
dromes from the age of 5 years, and for
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schizophrenia and psychosis from the age of 18 years;
and (2) aripiprazole for schizophrenia from the age of
15 years, and for moderate to severe manic episodes of
bipolar I disorder in adolescents aged 13 years or older.
Therefore, many prescriptions of AP are off-label and at
discretion of the practitioner.14 15
Importantly, many major AEs in children and adoles-
cents treated with AP have been reported in the litera-
ture.6 16–18 19 SGA compounds have distinct proﬁles of
secondary effects20 21 and at least some compounds (eg,
olanzapine) have more AEs in young patients than in
adults.22 The most common AEs of SGAs are metabolic
(weight gain, obesity, dyslipidemia, hyperglycaemia, diabetes,
insulin resistance), cardiac,10 neuromoto (somnolence/
sedation, extrapyramidal syndrome, akathisia, dystonia,
catatonia) and endocrine (hyperprolactinaemia).23–26
Several authors expressed concerns about the conse-
quences of SGAs after long-term exposure in this popu-
lation.20 27 28 Indeed, the paediatric population treated
by AP is at high risk of AEs.16 29 Yet, AEs are often
poorly monitored. For example, among children, meta-
bolic monitoring is carried out about two times less than
in the adult population.30
The Canadian Alliance for Monitoring Effectiveness and
Safety of Antipsychotics in children (CAMESA) published
recommendations for monitoring children and adoles-
cents treated with SGA drugs based on a meta-analysis of
studies conducted between 1996 and 201031 32 The
American Diabetes Association, American Psychiatric
Association, North American Association for the Study of
Obesity and the American Association of Clinical
Endocrinologists subsequently issued a joint consensus
that expanded the FDA screening recommendations to
include a monitoring protocol for children and adoles-
cents starting treatment with SGAs.30 However, these
recommendations are based on a limited amount of
studies. In a recent experts’ panel discussion on unmet
needs, experts highlighted the need for more speciﬁc
research given the numerous issues raised in paediatric psy-
chopharmacology including: “the frequent off-label pre-
scription of medications to children and adolescents based
exclusively on data from randomized controlled studies
involving adult patients; the frequent lack of age-speciﬁc
dose, long-term efﬁcacy and tolerability/safety data; […];
the current lack of biomarkers to predict treatment
response and severe AEs; the effective dissemination of
evidence-based treatments to the general public, to better
inform patients and families of the beneﬁts and risks of
pharmacological interventions during development”.33
In conclusion, the published data concerning AEs of
the AP treatment in the paediatric population are cur-
rently insufﬁcient, limiting the development of standar-
dised recommendations, essential to improve the safe use
of drugs in child psychiatry. Moreover, a better under-
standing of AEs of AP in paediatric patients is needed in
order to improve the beneﬁt—risk ratio. In addition,
more secure prescriptions should help to reduce global
healthcare costs of child psychiatry patients.
METHODS/DESIGN
Ethical consideration, funding and registration
ETAPE was funded and authorised by the French
National Agency for Medicines and Health Products
Safety (ANSM, number 2012-004546-15). The study
protocol was approved by the Local Ethics Committee of
the principal investigator (MLM) ‘Sud Méditerrané V’
(number 12.082). All patients and their parents signed
informed consent on enrolment in the study. The
ETAPE study has also been registered on ClinicalTrials.
gov (number NCT02007928). It started in April 2013
(the Gantt diagram is shown in ﬁgure 1).
Objectives
The main objective of this study is the evaluation of the
incidence of AE related to AP drugs in a French paediat-
ric population with no history of treatment with AP
drugs. Secondary objectives are the evaluation of risk
factors associated with the occurrence of AEs, persist-
ence of AEs at the end of the study, evaluation of risk
factors associated with changing AP drug, evaluation of
disorder’ severity, social functioning, therapeutic alli-
ance, quality of life, eating patterns and physical activity.
Trial design
ETAPE is a naturalistic prospective multicentre study.34 35
Patients were recruited over a period of 25 months (from
April 2013 to May 2015). A total of 200 patients have
been enrolled in 10 University Departments of Child and
Adolescent Psychiatry (Children’s Hospitals of NICE
CHU-Lenval, NICE; University Hospital Pitié Salpêtrière,
Paris; Nantes University Hospital, Nantes; Lille University
Hospital, Lille; Nancy University Hospital, Nancy; Esquirol
Hospital, Limoges; Lyon University Hospitals (HCL Lyon,
CH Vinatier, St Jean de Dieu); Toulouse University Hospital,
Toulouse; Hospital Fondation Vallée, Gentilly; Poitiers
University Hospital, Poitiers; Monaco Hospital) (ﬁgure 2).
Both inpatients and outpatients have been included in
the study. The follow-up for each patient is 12 months.
Thus, the monitoring period will end in May 2016.
Patients have been included up to 28 days after the intro-
duction of AP drug. Assessments are performed at inclusion
and at 3, 6, 9 and 12 month follow-up (M3, M6, M9, M12).
Results of laboratory assessment and ECG up to 90 days
prior to and 28 days after initiation of AP treatment are con-
sidered for the inclusion visit. Follow-up visits are scheduled
at 3, 6, 9 and 12 months after the introduction of AP drug
(± 14 days). Follow-up and clinical assessments are speciﬁed
in table 1. Given the naturalistic design, prescribing deci-
sions will remain free and independent of the study.
Practitioners will take all decisions about change or cessa-
tion of AP medication according to their usual clinical prac-
tice. Each centre will be responsible for the interpretation
of all additional examinations performed during the study.
Inclusion criteria
The study was proposed to AP-naive children and adoles-
cents with a practitioner’s prescription of AP. Participants
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accessed the study either by direct access at the study sites
or by referral by a general practitioner or specialists pre-
scribing the medication. Inclusion criteria were as follows:
▸ Male or female aged from 6 to 18 years
▸ Treated by AP drug for less than 28 days
▸ Never having received AP treatment before, or having
received AP for less than 3 months and discontinued
6 months prior to the study
▸ Informed consent of parents or guardian
▸ Informed consent of child aged 12 years and older
▸ Consent of child aged under 12 years
▸ Afﬁliation to French social security
Exclusion criteria
Since our goal was to conduct a naturalistic study of all
types of prescriptions of AP, we did not retain frequently
used exclusion criteria such as off-label prescription,
patients with severe condition (eg, suicidal behaviour;
hospitalisation; comorbid organic condition) and patients
with intellectual disability. Therefore, the only exclusion
Figure 2 Inclusion per centre.
Legend of figure 2: Less than 6
inclusions per centre (Fondation
Vallée, Gentilly; Nancy University
Hospital; Poitiers University
Hospital; Monaco Hospital) N=12
(6%).
Figure 1 Gantt diagram of the ETAPE study. ANSM, French National Agency for Medicines and Health Products Safety;
ETAPE, Etude de la Tolérance des AntiPsychotique chez l’Enfant.
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criterion was refusal or withdrawal of consent by the
patient or his/her parents.
Measures
Quantitative and qualitative measures are assessed
during the study (summary in table 1): clinical para-
meters (eg, body weight), laboratory assessment (eg,
blood cholesterol), ECG (eg, QTc interval), semistruc-
tured interviews to assess main diagnosis at inclusion
and after 12 month follow-up (Kiddie-SADS,41 and/or
MINI/MINI-Kid42), several clinical heteroassessments
with a speciﬁc rating scale (eg, the Modiﬁed
Bush-Francis Catatonia Rating Scale, BFCRS40 53), and
several self-report questionnaires (eg, Pediatric Adverse
Event Rating Scale, PAERS47).
Data collection process
Each investigator of the different study centres (child
psychiatrist, clinical psychologist, physician, paediatri-
cian, cardiologist) is responsible for collecting and enter-
ing data on the paper CRF at the time of the visit. Data
control for quality and regulation requirement is rea-
lised in each every ﬁve inclusions centre by the
monitoring clinical research assistant. Results will be
entered by the clinical research assistants of the NICE
study centre in the database. Double-check in order to
avoid missing data or ﬁlling errors will be carried out
before freezing of the database. Data extraction and ana-
lysis of the database (Open Clinica V.3.1.3 Community
Edition) will be performed by the Department of Clinical
Research and Innovation (DRCI) at NICE University
Hospital (data and metadata) after freezing.
Statistical analysis
Statistical analysis will be conducted by DRCI at NICE
University Hospital using SAS Enterprise Guide V.5.1
(Copyright (c) 1999–2006 by SAS Institute Inc, Cary,
North Carolina, USA). A descriptive analysis of all the
parameters collected at baseline and during follow-up will
be performed. For continuous variables (age, weight,
body mass index, etc), indicators such as the mean, SD
and range values will be calculated. Categorical data will
be presented by means of frequency (n, %).
Changes in the parameters and in the distribution of
categorical variables from baseline to follow-up points
will be tested with univariate analysis using appropriate
Table 1 ETAPE study procedure and evaluation criteria
Selection Inclusion M3 M6 M9 M12
Inclusion criteria ×
Informed consent ×
Somatic parameters weight, height, BMI, waist circumference, blood pressure,
temperature
– × × × × ×
Tanner stage – × – × – ×
AIMS36
SAS37 38 – × × × × ×
BARS39
BFCRS40
Laboratory assessment
Full blood count, liver enzymes, creatine phosphokinase, glycaemia,
cholesterol (total, HDL, LDL), triglycerides, hsCRP,
– × × × × ×
Prolactin, insulin, HbA1c, HOMA – × × × – ×
Vitamin D – × × – – ×
Thyroid hormones – × – – – ×
ECG, QTc interval – × – × – ×
Semistructured interview
K-SADS41
MINI/MINI-kid42
– × – – – ×
Clinician questionnaires
CGI-S43 44
– × × × × ×
CGAS45 46 – × – × – ×
PAERS47 – × × × × ×
Patient Questionnaires
QEWP48 – × × × × ×
HAQ49 50 – – × × × ×
SDS51 – × × × × ×
Dennison52 – × × × × ×
AIMS, abnormal involuntary movement scale; BARS, barnes akathisia rating scale; BFCRS, bush francis catatonia rating scale; BMI, body
mass index; CGAS: clinical global assessment scale; CGI-S, clinical global impression scale; ECG, electrocardiogram; HAQ, helping alliance
questionnaire; HDL, high-density lipoprotein; hs-CRP, high sensitivity C-reactive protein; HbA1c, glycated haemoglobin; HOMA, insulin
resistance; K-SADS, SAS, simpson and angus scale; LDL, low-density lipoprotein; MINI, mini international neuropsychiatric interview;
PAERS, pediatric adverse event rating scale; QEWP, questionnaire of eating and weight patterns; schedule for affective disorders and
schizophrenia for school age children; SDS, sheehan disability scale.
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testing according to the type of variable and distribution
with a level of signiﬁcance for the p value ﬁxed at <0.05.
In addition, multivariate analysis will be carried out.
An intention-to-treat approach will be used; this means
that patients who will be lost to follow-up will be censored
at the time of the last visit they attended and included
in the analysis. Survival analysis techniques will be per-
formed using Cox analysis for binary outcomes and gen-
eralised models for continuous variables. Missing data will
also be handled by using the Last Observation Carried
Forward method.
OUTCOMES
The implementation of this national study should help
in raising awareness and educating all French practi-
tioners (child psychiatrists, psychiatrists, paediatricians,
general physicians) about AEs of AP in young people.
The study will also enable better characterisation of the
prescription of AP drugs in children and adolescents
and evaluate the incidence of AEs related to AP drugs in
a French population with no history of taking AP drugs.
The secondary objectives of the ETAPE study are the
assessment of risk factors associated with the occurrence
of AEs (eg, age at onset of treatment, pubertal status at
baseline, age at onset of disorder for which the prescrip-
tion of an SGA drug was indicated, type of AP treatment,
concomitant treatment, Diagnostic and Statistical Manual
Fourth Edition (DSM-IV) diagnosis). In addition, these
items will help to identify risk factors associated with
change of AP treatment. The course of disorder’ severity,
social functioning, therapeutic alliance, quality of life,
eating patterns and physical activity during follow-up will
also be analysed.
The results will serve to:
▸ Help practitioners for prescription decisions
▸ Reinforce monitoring of AEs related to AP drugs
▸ Develop recommendations for AP prescription and
follow-up by adding original data from a naturalistic
study
▸ Improve the safety of AP drugs in child and adoles-
cent psychiatry
The results will further help to develop quality stan-
dards and monitoring methods for the prescription of
AP in order to improve the beneﬁt/risk ratio.
DISCUSSION
The results of this study are very important as AEs of
antipsychotic treatment are sometimes overlooked in
current practice in child psychiatry. In addition, few studies
target the antipsychotic-naive paediatric population.
The ETAPE study proposes a methodology enabling
an exhaustive search for AE. Early identiﬁcation and
better understanding of AE will help to improve mental
healthcare of the paediatric population, and also reduce
the costs of the treatment of AE.
Limitations of the study: The paediatric psychiatric
population is very difﬁcult to follow up reliably. There is
a high risk of loss to follow-up, which is estimated to be at
least 20%. The size of the sample could be limited by these
factors. The clinical scales used to assess neuromuscular
AEs are validated in the adult population, which might be
a limitation for analyses in young patients. Secondary
analyses may be limited by the number of patients in
each subgroup.
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